UNSPSC 51171972: Alglucerase

This classification denotes an enzyme replacement preparation with the molecular formula C2532H3854N672O711S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27T56C7KK0, more generally known as alglucerase. European Medicines Agency schedules alglucerase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05322MIG. The term ALGLUCERASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 7, no3, 1993, list 33.

UNSPSC 51171972 Alglucerase (Commodity) covers pharmaceutical and diagnostic products purchased by state and local governments for clinical, correctional, and population health settings. The code encompasses enzyme replacement therapies and related pharmaceutical products as well as laboratory testing and specimen collection services integrated into state health and corrections workflows. State and local issuing bodies under this code include county corrections departments, state health and human services agencies, and cooperative purchasing alliances representing multi-state government health systems. The scope of work centers on pharmaceutical supply chain management—including direct contracting with manufacturers, acquisition through authorized wholesalers, and compliance with regulatory frameworks such as cGMP, DSCSA, and FDA requirements—alongside specimen collection and drug testing services that support offender monitoring, public health surveillance, and employee health programs.

Recent activity shows issuing bodies across Texas and the upper Midwest. Collin County Community Supervision and Corrections Department (Texas) posted RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026; the scope includes staffing two collection sites in Plano and McKinney, operation of an Interactive Voice Response system, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies including oral fluid and hair testing, with annual testing demand of approximately 25,031 tests. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities regarding direct-to-manufacturer prescriptions and pharmacy benefit program optimization, signaling early-stage procurement planning in pharmaceutical supply chain strategy. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon; awards require products to be available by May 15, 2026, with effective dates July 1, 2026, and a two-year initial contract term. All three opportunities emphasize regulatory compliance, authorized distributor networks, and multi-award structures reflecting patient safety and therapeutic diversity priorities.